Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA® (aflibercept)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA® (aflibercept)

Momenta Pharmaceuticals (MNTA) PT Raised to $15 at Stifel Following Positive M281 MAD Data, EYLEA Biosimilar Unveiling

January 5, 2018 12:40 PM EST

Stifel analyst Alex Schwartz raised his price target on Momenta Pharmaceuticals (NASDAQ: MNTA) to $15.00 (from $12.00) while maintaining a Hold rating after the company announced positive topline data from the Phase 1 trial with M281.

Schwartz commented, "The anti-FcRn antibody demonstrated a favorable safety profile... More

Mylan (MYL) PT Raised to $44 at BofA/Merrill Lynch Following Generic Estrace Cream Approval

January 4, 2018 8:08 AM EST

BofA/Merrill Lynch raised its price target on Mylan (NASDAQ: MYL) to $44.00 (from $41.00) while maintaining a Neutral rating following the recent approval of generic Estrace Cream, Allergans womens health brand with $375m net sales. MYL recently launched (12/29) g-Estrace followed by an authorized... More